Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway.
Saved in:
| Title: | Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway. |
|---|---|
| Authors: | Maiuthed A; Department of Pharmacology, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.; Centre of Biopharmaceutical Science for Healthy Ageing, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand., Huebner K; Department of Experimental Tumor Pathology, Universitätsklinikum, Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.; Institute of Pathology, Universitätsklinikum, Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Erlangen, Germany., Erlenbach-Wuensch K; Institute of Pathology, Universitätsklinikum, Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Erlangen, Germany., Hampel C; Department of Experimental Tumor Pathology, Universitätsklinikum, Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.; Institute of Pathology, Universitätsklinikum, Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Erlangen, Germany., Thalheim D; Department of Experimental Tumor Pathology, Universitätsklinikum, Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.; Institute of Pathology, Universitätsklinikum, Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Erlangen, Germany., Vial-Roehe A; Department of Pathology, Federal University of Health Sciences of Porto Alegre (UFCSPA), Porto Alegre, Brazil., Nutho B; Department of Pharmacology, Faculty of Science, Mahidol University, Bangkok, Thailand., Merkel S; Department of Surgery, Universitätsklinikum, Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Erlangen, Germany., Hartmann A; Institute of Pathology, Universitätsklinikum, Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Erlangen, Germany., Chanvorachote P; Center of Excellence in Cancer Cell and Molecular Biology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.; Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand., Schneider-Stock R; Department of Experimental Tumor Pathology, Universitätsklinikum, Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.; Institute of Pathology, Universitätsklinikum, Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.; Adjunct Professor, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand. |
| Source: | Molecular oncology [Mol Oncol] 2026 Apr; Vol. 20 (4), pp. 1022-1040. Date of Electronic Publication: 2025 Nov 03. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101308230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0261 (Electronic) Linking ISSN: 15747891 NLM ISO Abbreviation: Mol Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1878-0261 |
|---|---|
| DOI: | 10.1002/1878-0261.70150 |
